Why is "Abemaciclib" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-29 14:16:18
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer—comparing real-world outcomes in England to the MONARCH-2 trial - Nature
-
Abemaciclib Plus Endocrine Therapy Provides OS Benefit in HR+/HER2-Negative Breast Cancer - OncLive
-
Neoadjuvant Abemaciclib Plus Letrozole: Could Some Patients Avoid Chemotherapy? - Docwire News
-
Imlunestrant With or Without Abemaciclib Effective in Treating ER+, HER2- Advanced Breast Cancer That Resists Standard Therapy - Memorial Sloan Kettering Cancer Center
-
Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer - CancerNetwork
-
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy - Eli Lilly
-
Abemaciclib Significantly Improves Overall Survival in High-Risk Early Breast Cancer - Targeted Oncology
-
Yukinori Ozaki: New Trial of Abemaciclib in HR+/HER2− Locoregional Breast Cancer Recurrence - Oncodaily
-
Mayo Clinic collaborates on new drug study showing improved survival for early breast cancer - Mayo Clinic News Network
-
Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer - AJMC
-
Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer - Pharmacy Times
-
Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial - Nature
-
Abemaciclib Monotherapy Shows Efficacy After CDK4/6 Inhibition in HR+/HER2– Breast Cancer - OncLive
-
monarchE Shows Significant OS Benefit With Adjuvant Abemaciclib in High-Risk HR+, HER2− Early Breast Cancer - Docwire News
-
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer - Eli Lilly
-
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial - Nature
-
monarchE Shows Survival Benefit With Adjuvant Abemaciclib Across All Nodal Burdens - Docwire News
-
Optimizing Abemaciclib Tolerability and Dose Escalation - OncLive
-
Proton-pump inhibitors and palbociclib or abemaciclib in endocrine-sensitive breast cancer treatment - Nature
-
Adjuvant Abemaciclib Plus Endocrine Therapy Improves OS in High-Risk HR+/HER2– Breast Cancer - OncLive
-
Sustained Abemaciclib Benefit in High-Risk Breast Cancer: MonarchE Trial Update - Targeted Oncology
-
Abemaciclib Shows Encouraging Activity in Recurrent/Progressive Meningioma - CancerNetwork
-
Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities - Nature
-
Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): phase 2 results from ELEVATE, an open-label, umbrella study - OncLive
-
Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer - CancerNetwork
-
monarchE Trial: How Abemaciclib Changed the Adjuvant Landscape in High-Risk HR+ Early Breast Cancer - Oncodaily
-
monarchE Trial at ESMO 2025: Adjuvant Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk HR+, HER2− Early Breast Cancer - Oncodaily
-
MonarchE: Primary Overall Survival Results Of Adjuvant Abemaciclib Plus Endocrine Therapy For HR+, HER2-, High-Risk Early Breast Cancer - OncLive
-
Abemaciclib or Ribociclib: Choosing a CDK4/6 Inhibitor in ER-Positive/HER2-Negative Stage III Early Breast Cancer in the Adjuvant Setting - ASCO Daily News
-
Differentiating Between Abemaciclib and Ribociclib - OncLive
-
Abemaciclib early access - an Italian experience - Frontiers
-
“Great News”: Updated Data Back Elacestrant as Potential Backbone for Breast Cancer Combo Regimens - Oncology News Central
-
Elacestrant-Based Combinations Show Efficacy, Safety in ER+, HER2-Negative Breast Cancer - OncLive
-
Risk factors for adverse reactions caused by abemaciclib in breast cancer therapy - Frontiers
-
Abemaciclib Improves PFS in Tough-to-Treat Meningiomas - Targeted Oncology
-
TRADE Study Insights: A New Approach to Improve Abemaciclib Tolerability in Breast Cancer Care - Journal of Hematology Oncology Pharmacy
-
Survival Data Strengthens Case for Abemaciclib in High-Risk Breast Cancer - Targeted Oncology
-
Press Release: Verzenio (Abemaciclib) Increases Overall Survival in High-Risk HR+, HER2- Early BC - Oncodaily
-
Abemaciclib Ups Overall Survival in High-Risk Breast Cancer - Medscape
-
Abemaciclib Plus Endocrine Therapy Improves Survival in Patients With HR+/HER2– Breast Cancer - Pharmacy Times
-
Common Adverse Events Associated With CDK4/6 Inhibitors - Oncology Nursing News
-
Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer - Pharmacy Times
-
Abemaciclib Displays Efficacy, Tolerability in HIV-Associated and HIV-Negative Kaposi Sarcoma - OncLive
-
Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study - Oncology Central
-
Long-term phase III data reinforce the benefits of CDK4/6 inhibitors in early breast cancer - ESMO Daily Reporter
-
Abemaciclib Plus Endocrine Therapy Improves Survival in High-Risk HR+, HER2– Early Breast Cancer - Docwire News
-
Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034 - Yahoo Finance
-
Indirect Treatment Comparison Evaluates Imlunestrant Plus Abemaciclib Against Fulvestrant Combination Therapy - Pharmacy Times
-
EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer - Docwire News
-
Selection Considerations for Abemaciclib Versus Ribociclib in Early HR+/HER2- Breast Cancer: Efficacy, Safety, and Long-Term Outcomes - Pharmacy Times
-
Adjuvant Therapy Advances in HR+ Breast Cancer: Updates From NATALEE, monarchE, and lidERA - Docwire News
-
Abemaciclib impairs glioblastoma sphere formation by targeting the GSK3β-mediated transcriptional regulation of CD44 and TCF7L2 - Nature
-
Imlunestrant Plus Abemaciclib Provides Consistent Benefit Across Key Subgroups of ER+ Advanced Breast Cancer - OncLive
-
Metformin Plus Letrozole and Abemaciclib Induces CRs in ER+ Recurrent Endometrial Cancer - OncLive
-
Real-World Study Shows Differences in Efficacy Among CDK4/6 Inhibitors for Advanced Breast Cancer - Targeted Oncology
-
postMONARCH ctDNA Analysis Underscores Benefit of Abemaciclib Plus Fulvestrant in HR+ Advanced Breast Cancer - OncLive
-
ASCO 2025: CLONEVO: Preoperative Abemaciclib for Cisplatin Ineligible MIBC with Molecular Response Assessment - UroToday
-
Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment - Yahoo Finance
-
Management of Node-Positive, High-Risk HR+/HER2– Early Breast Cancer in Adults - Cancer Therapy Advisor
-
FDA Grants Fast Track Status to ZEN-3694 Plus Abemaciclib for Unresectable or Metastatic NUT Carcinoma - OncLive
-
42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US - CancerNetwork
-
Data Bolster Support for Imlunestrant (Inluriyo) in ER-Positive, HER2-Negative Advanced Breast Cancer - Oncology News Central
-
Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting - Eli Lilly
-
Kaplan-Meier Plot of Invasive Disease–Free Survival, Additional Follow-Up Analysis — Cohort 1 Ki-67 High Population - National Institutes of Health (.gov)
-
PROs Favor Imlunestrant With/Without Abemaciclib in ER+, HER2– Breast Cancer - CancerNetwork
-
Considerations for the Use of Abemaciclib vs Ribociclib in Breast Cancer - Pharmacy Times
-
Adjuvant CDK4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer - Cancer Therapy Advisor
-
Eli Lilly’s Verzenio boosts OS in breast cancer as Novartis rivalry heats up - Clinical Trials Arena
-
Imlunestrant Regimens Sustain Efficacy Benefit in ER+/HER2– Breast Cancer - Targeted Oncology
-
Meningiomas Slowed By Targeted Therapy, Shows NCI Clinical Trials Network Group - Inside Precision Medicine
-
EMBER-3 Trial: Imlunestrant in ER+/HER2− Breast Cancer - Oncodaily
-
Abemaciclib Dose Escalation for Early Stage HR+/HER2– Breast Cancer - HMP Global Learning Network
-
ICYMI: Highlights From ESMO 2025 - AJMC
-
Komal Jhaveri: OS Benefit with Adjuvant Abemaciclib in High-Risk Breast Cancer - Oncodaily
-
ESMO 2025: Eli Lilly’s Verzenio extends survival in high-risk early breast cancer - Clinical Trials Arena
-
Elacestrant combos confer ‘clinically meaningful’ outcomes for advanced breast cancer - Healio
-
Vidal Discusses Differences in Duration and AEs With Adjuvant CDK4/6i in Breast Cancer - Targeted Oncology
-
First Survival Win for CDK4/6 Inhibitors in High-Risk Early-Breast Cancer - MedPage Today
-
30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial - CancerNetwork
-
CLONEVO Study: Targeting Cyclin D1 Amplifications in Bladder Cancer with Abemaciclib - Bishoy Faltas - UroToday
-
ESMO: Eli Lilly's Verzenio secures overall survival win, bolstering early breast cancer case - Fierce Pharma
-
PostMONARCH: Abemaciclib Combo Effective After CDK4/6i Failure - Docwire News
-
New Hope for Advanced Breast Cancer: Camizestrant Plus CDK4/6 Inhibitors Shows Promise in Phase 1 Trial - Docwire News
-
VIDEO: Abemaciclib dose-escalation strategy promising for some patients with breast cancer - Healio
-
San Antonio Breast Cancer Symposium 2025 - The Lancet
-
Antiproliferative and Apoptotic Effects of Mono/Combined Treatment of Abemaciclib and Regulation of Neuroblastoma-Related miRNAs - Wiley
-
Neeraj Agarwal: Abemaciclib Plus Abiraterone vs Abiraterone in mCRPC Prostate Cancer - Oncodaily
-
Harold Burstein: FDA Decision on Oral SERD Imlunestrant and Combo With Abemaciclib - Oncodaily
-
Lilly's Verzenio shows survival benefit in early breast cancer - FirstWord Pharma
-
Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer - OncLive
-
Dr Konstantinopoulos on the Safety of Letrozole, Abemaciclib, and Metformin in ER+ Recurrent Endometrial Cancer - OncLive
-
Eli Lilly’s Abemaciclib Combo Pushes Deeper Into Advanced Prostate Cancer - TipRanks
-
Adverse Event Profiles Associated with CDK4/6 Inhibitors - Pharmacy Times
-
Ocular toxicity events of cyclin-dependent kinase 4/6 inhibitors in breast cancer: a pharmacovigilance study based on the faers database - Frontiers
-
Verzenio Side Effects: Common, Mild, Serious, and Long Term - Healthline
-
An oral cancer drug shows promise against aggressive brain tumors - Medical Xpress
-
Lilly shifts ambition for broader oral SERD label to largest oncology trial in company history - Fierce Pharma
-
EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer - Oncodaily
-
PALMARES-2 Study Highlights Variable Efficacy of CDK4/6 Inhibitors in HER2-Negative Advanced Breast Cancer - Docwire News
-
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer - CancerNetwork
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.